Pathophysiology of spironolactone-induced gynecomastia.
Peripheral blood levels of testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone and the metabolic clearance rates of testosterone and estradiol, as well as the peripheral conversion of testosterone into estradiol, were measured in 16 patients with hypertension. Six of these patients were treated with spironolactone and developed gynecomastia. The other 10 patients served as control subjects. The blood testosterone level in the spironolactone-treated group (2.7 +/- 0.5 ng/ml) was significantly less (P less than 0.02) than in the control group (4.4 +/- 0.4 ng/ml). On the other hand, blood estradiol levels in the spironolactone group (30 +/- 4 pg/ml) were significantly greater (P less than 0.01) than in the control group (13 +/- 2 pg/ml). These changes were primarily due to significant increases in the metabolic clearance rate of testosterone (P less than 0.02) and in the rate of peripheral conversion of testosterone into estradiol (P less than 0.001) in the spironolactone-treated group. Thus, spironolactone does alter the peripheral metabolism of testosterone resulting in changes in the ratio of testosterone to estradiol, which could contribute to the production of gynecomastia.
D000328:Adult; D004958:Estradiol / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism; D006177:Gynecomastia / Q000139:chemically induced* / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013739:Testosterone / Q000378:metabolism
D004967:Estrogens; D013148:Spironolactone; D013739:Testosterone; D004958:Estradiol